截至3月31日，睿昂基因股东户数3990.00，较上期减少6.54%；人均流通股13998股，较上期增加 6.99%。2025年1月-3月，睿昂基因实现营业收入5473.80万元，同比减少14.72%；归母净利润335.50万 元，同比增长529.26%。 分红方面，睿昂基因A股上市后累计派现1005.41万元。 8月26日，睿昂基因涨9.95%，成交额1.48亿元。两融数据显示，当日睿昂基因获融资买入额2089.01万 元，融资偿还1810.46万元，融资净买入278.54万元。截至8月26日，睿昂基因融资融券余额合计7103.01 万元。 融资方面，睿昂基因当日融资买入2089.01万元。当前融资余额7103.01万元，占流通市值的3.70%，融 资余额超过近一年80%分位水平，处于高位。 融券方面，睿昂基因8月26日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海睿昂基因科技股份有限公司位于上海市奉贤区汇丰西路1817弄147号，成立日期2012年2 月17日，上市日期2021年5 ...

Core Insights - The report highlights the significant compensation of CFOs in the A-share market, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for 2024 [1] - The pharmaceutical and biotechnology sector shows a higher average CFO salary of 919,700 yuan, which is 12.8% above the overall market average [1] - In Shanghai, the average CFO salary in the pharmaceutical sector reaches approximately 1,139,100 yuan, 39.8% higher than the market average, reflecting the high operational costs and talent competition in the region [1] CFO Salary Rankings - The top ten CFOs in Shanghai's pharmaceutical sector include notable figures such as Shen Bo from Shanghai Medical with a salary of 3.054 million yuan and a growth rate of 5.75% [2] - Li Yan from Ruian Gene ranks seventh with a salary of 1.573 million yuan, marking a 15.49% increase from the previous year [2][3] Company Performance - Ruian Gene reported a total revenue of 242 million yuan for 2024, a decline of 6.16% year-on-year, and a net profit of -16 million yuan, indicating a significant downturn [4] - The company's stock price fell by 48.46%, with a market capitalization of 1.03 billion yuan by the end of 2024, alongside facing compliance penalties [5] Talent Competition - The report emphasizes the strategic importance of top-tier financial executives in high-value industries, driven by the dual factors of core regional advantages and high-value industry characteristics [5]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688217 证券简称：睿昂基因 公告编号：2025-034 上海睿昂基因科技股份有限公司(以下简称"公司")全资子公司上海源奇生 物医药科技有限公司于近日收到政府补助资金共人民币 176.29 万元，为与收益 相关的政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号—政府补助》的相关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理 以及对公司损益的影响最终以审计机构年度审计确认后的结果为准。敬请投资 者注意投资风险。 特此公告。 上海睿昂基因科技股份有限公司董事会 2025 年 7 月 2 日 上海睿昂基因科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获取补助的基本情况 ...

关于对上海睿昂基因科技股份有限公司 2024 年度审计报告出具带强调事项段无保留意见 的专项说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 关于对上海睿昂基因科技股份有限公司 2024年度审计报告出具带强调事项段无保留意见 的专项说明 中汇会专[2025]4209号 上海证券交易所: 我们接受委托,依据中国注册会计师审计准则审计了上海睿昂基因科技股份 有限公司(以下简称睿昂基因公司)2024年12月31日的合并及母公司资产负债表, 2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有 者权益变动表以及财务报表附注,并于2025年4月16日出具了中汇会审[2025]4206 号带强调事项段无保留意见的审计报告。 表整体的重要性水平为183.77万元。睿昂基因公司近年来经 ...

Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of Shanghai Ruiang Gene Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [2][14]. Group 1: Meeting Procedures - The annual general meeting was convened by the company's board of directors, with the notice published 20 days prior to the meeting date [4][5]. - The meeting utilized a combination of on-site and online voting methods, with specific time slots designated for each voting method [5][14]. Group 2: Attendance and Voting - A total of 33 shareholders and their proxies attended the meeting, representing 17,949,661 shares, which is 32.5256% of the total voting shares [6]. - The meeting included 3 shareholders present on-site, representing 10,804,197 shares (19.5777% of total voting shares), while 30 shareholders participated via online voting [6][7]. Group 3: Resolutions Passed - The meeting approved several resolutions, including: - The 2024 Board of Directors' Work Report, with 99.3652% approval from attending shareholders [8]. - The 2024 Supervisory Board's Work Report, also receiving 99.3652% approval [9]. - The 2024 Financial Settlement Report, with the same level of approval [10]. - The 2025 Financial Budget Report, approved by 99.3391% of attending shareholders [10]. - The 2024 Profit Distribution Plan, receiving 99.3652% approval [10]. - The 2024 Annual Report and its summary, with 99.3652% approval [11]. - The 2025 Director Remuneration Plan, approved by 99.2735% of attending shareholders [12]. - The 2025 Supervisor Remuneration Plan, also receiving 99.2735% approval [12]. - The proposal for a comprehensive credit limit application to banks for 2025, approved by 99.2980% of attending shareholders [13]. Group 4: Legal Compliance - The legal opinion confirms that the meeting's convening, attendance, voting procedures, and resolutions comply with the Company Law, Securities Law, and other relevant regulations [14].

证券代码：688217 证券简称：睿昂基因 公告编号：2025-033 上海睿昂基因科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 20 日 （二） 股东大会召开的地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 普通股股东人数 | 33 | | 2、出席会议的股东所持有的表决权数量 | 17,949,661 | | 普通股股东所持有表决权数量 | 17,949,661 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.5256 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.5256 | ...

上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2024 年年度股东大会的 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2024 年年度股东大会的 法律意见书 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本 次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称《" 公司法》"）、 《上市公司股东会规则》等法律、法规和其他规范性文件以及《上海睿昂基因科 技股份有限公司章程》（以下简称《" 公司章程》"）的有关规定，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原 ...

Core Viewpoint - Shanghai Ruian Gene Technology Co., Ltd. is facing challenges in the biopharmaceutical industry, with a focus on maintaining stability and enhancing governance while navigating a decline in revenue and profit [5][6][10]. Meeting Procedures - The company has established guidelines for the annual shareholder meeting to ensure order and efficiency, requiring attendees to verify their identity and register in advance [1][2]. - Shareholders have the right to speak, inquire, and vote, with specific procedures for raising questions and participating in discussions [3][4]. Financial Performance - In 2024, the company reported a revenue of 242.31 million yuan, a decrease of 6.16% year-on-year, and a net profit attributable to shareholders of -15.76 million yuan, down 298.78% [6][21]. - The core business related to tumors generated revenue of 234.95 million yuan, reflecting a decline of 2.26% [6][21]. Business Developments - The company has made progress in its core business areas, including the addition of 75 new hospital admissions for its products, with specific gains in leukemia and lymphoma product admissions [7][8]. - The company has focused on digital and intelligent upgrades in laboratories, establishing a joint laboratory with Peking University to enhance AI applications in medical technology [8]. Governance and Compliance - The board of directors has adhered to legal and regulatory requirements, ensuring compliance in decision-making and operations, with all submitted proposals approved by shareholders [10][11]. - The supervisory board has conducted oversight on financial operations and internal controls, confirming that the company operates within legal frameworks and maintains financial integrity [18][19]. Future Plans - The company aims to enhance its research and development capabilities, focusing on molecular diagnostics for blood cancers and infectious diseases, with a commitment to affordable precision medicine [13][14]. - Plans for 2025 include advancing clinical projects and improving marketing mechanisms to increase product admissions in hospitals [14][15].

上海睿昂基因科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2024 年年度股东大会 会议资料 2025 年 6 月 上海睿昂基因科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024 | 年年度股东大会会议须知 | | 3 | | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | | 5 | | 2024 | 年年度股东大会会议议案 | | 7 | | | 议案一《关于 2024 | 年度董事会工作报告的议案》 | 7 | | | 议案二《关于 2024 | 年度监事会工作报告的议案》 14 | | | | 议案三《关于 2024 | 年度独立董事述职报告的议案》 18 | | | | 议案四《关于 2024 | 年度财务决算报告的议案》 | 19 | | | 议案五《关于 2025 | 年度财务预算报告的议案》 | 26 | | | 议案六《关于公司 2024 | 年度利润分配预案的议案》 28 | | | | 议案七《关于<2024 | 年年度报告>及其摘要的议案》 ...